Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zai Lab Ltd ( (HK:9688) ) has issued an announcement.
Zai Lab Limited announced that its partner Amgen has stopped the Phase 1b/3 FORTITUDE-102 trial for bemarituzumab, a treatment for first-line gastric cancer, due to inadequate efficacy. This decision may impact Zai Lab’s operations and its positioning in the oncology market, as the company will continue to collaborate with Amgen for further updates.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing and commercializing innovative medicines. The company operates in the healthcare industry, with a market focus on addressing unmet medical needs in cancer, autoimmune, and infectious diseases.
Average Trading Volume: 14,858,643
Technical Sentiment Signal: Sell
Current Market Cap: HK$23.45B
Learn more about 9688 stock on TipRanks’ Stock Analysis page.